Movement Alert｜Hansoh Pharma Rises 3.51% in Regular Trading, Core ADC Drug HS-20093 Achieves OS Primary Endpoint in Phase III SCLC Trial

Market Focus07-13

On July 13, Hansoh Pharma rose 3.51% in regular trading, trading at HKD 32.78/share, with turnover of HKD 78.47 million.

On the news front, the company announced on July 10 that its self-developed B7-H3 targeted antibody-drug conjugate (ADC) HS-20093 achieved the primary endpoint of overall survival (OS) in a pivotal Phase III clinical trial for small cell lung cancer (SCLC) patients who progressed or relapsed after platinum-containing regimens. Compared to topotecan, the drug demonstrated statistically significant and clinically meaningful improvement in OS, with the secondary endpoint of progression-free survival also showing consistent benefit.

This study represents the first global Phase III trial to confirm significant OS benefit from a B7-H3 ADC in small cell lung cancer. The company stated it will expedite communication with regulatory authorities and advance the new drug application in China. Notably, HS-20093 had previously been granted Breakthrough Therapy Designation by China's NMPA for esophageal squamous cell carcinoma and castration-resistant prostate cancer, underscoring its broad oncology potential.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153934748?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 09:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153934748","market":"us","top_or_hot":-1,"title":"Movement Alert｜Hansoh Pharma Rises 3.51% in Regular Trading, Core ADC Drug HS-20093 Achieves OS Primary Endpoint in Phase III SCLC Trial","media":"Market Focus","content":"<p><p>On July 13, Hansoh Pharma rose 3.51% in regular trading, trading at HKD 32.78/share, with turnover of HKD 78.47 million.</p><p>On the news front, the company announced on July 10 that its self-developed B7-H3 targeted antibody-drug conjugate (ADC) HS-20093 achieved the primary endpoint of overall survival (OS) in a pivotal Phase III clinical trial for small cell lung cancer (SCLC) patients who progressed or relapsed after platinum-containing regimens. Compared to topotecan, the drug demonstrated statistically significant and clinically meaningful improvement in OS, with the secondary endpoint of progression-free survival also showing consistent benefit.</p><p>This study represents the first global Phase III trial to confirm significant OS benefit from a B7-H3 ADC in small cell lung cancer. The company stated it will expedite communication with regulatory authorities and advance the new drug application in China. Notably, HS-20093 had previously been granted Breakthrough Therapy Designation by China's NMPA for esophageal squamous cell carcinoma and castration-resistant prostate cancer, underscoring its broad oncology potential.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hansoh Pharma Rises 3.51% in Regular Trading, Core ADC Drug HS-20093 Achieves OS Primary Endpoint in Phase III SCLC Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hansoh Pharma Rises 3.51% in Regular Trading, Core ADC Drug HS-20093 Achieves OS Primary Endpoint in Phase III SCLC Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-13 09:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 13, Hansoh Pharma rose 3.51% in regular trading, trading at HKD 32.78/share, with turnover of HKD 78.47 million.</p><p>On the news front, the company announced on July 10 that its self-developed B7-H3 targeted antibody-drug conjugate (ADC) HS-20093 achieved the primary endpoint of overall survival (OS) in a pivotal Phase III clinical trial for small cell lung cancer (SCLC) patients who progressed or relapsed after platinum-containing regimens. Compared to topotecan, the drug demonstrated statistically significant and clinically meaningful improvement in OS, with the secondary endpoint of progression-free survival also showing consistent benefit.</p><p>This study represents the first global Phase III trial to confirm significant OS benefit from a B7-H3 ADC in small cell lung cancer. The company stated it will expedite communication with regulatory authorities and advance the new drug application in China. Notably, HS-20093 had previously been granted Breakthrough Therapy Designation by China's NMPA for esophageal squamous cell carcinoma and castration-resistant prostate cancer, underscoring its broad oncology potential.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1153934748","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153934748","pubTimestamp":1783906980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 13, Hansoh Pharma rose 3.51% in regular trading, trading at HKD 32.78/share, with turnover of HKD 78.47 million.On the news front, the company announced on July 10 that its self-developed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"走势提醒|豪森医药常规交易涨3.51%，核心ADC药物HS-20093在SCLC III期试验中达到OS主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On July 13, Hansoh Pharma rose 3.51% in regular trading, trading at HKD 32.78/share, with turnover of HKD 78.47 million.On the news front, the company announced on July 10 that its self-developed B7-H3 targeted antibody-drug conjugate (ADC) HS-20093 achieved the primary endpoint of overall survival (OS) in a pivotal Phase III clinical trial for small cell lung cancer (SCLC) patients who progressed or relapsed after platinum-containing regimens. Compared to topotecan, the drug demonstrated statistically significant and clinically meaningful improvement in OS, with the secondary endpoint of progression-free survival also showing consistent benefit.This study represents the first global Phase III trial to confirm significant OS benefit from a B7-H3 ADC in small cell lung cancer. The company stated it will expedite communication with regulatory authorities and advance the new drug application in China. Notably, HS-20093 had previously been granted Breakthrough Therapy Designation by China's NMPA for esophageal squamous cell carcinoma and castration-resistant prostate cancer, underscoring its broad oncology potential.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153934748","isCrawlerRequest":true}